{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-049199","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.439121+00:00","generated_at":"2026-05-29T05:35:00.013869+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InspireMD enrolls first patient in CGUARDIANS II pivotal TCAR study for CGuard Prime","bullets":["First patient enrolled by Dr. Patrick Muck at Good Samaritan Hospital (TriHealth, Cincinnati).","Prospective, single-arm study: 50+ evaluable patients; acute device/technical success endpoints.","CEO targets FDA approval for CGuard Prime CAS indication in H1 2025; TCAR market ~30,000 procedures/year.","Over 60,000 CGuard devices sold globally; MicroNet mesh cited for protective outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-049199","json":"https://secwatch.observer/filing/0001493152-24-049199.json","markdown":"https://secwatch.observer/filing/0001493152-24-049199.md","text":"https://secwatch.observer/filing/0001493152-24-049199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224049199/0001493152-24-049199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224049199/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:35:00.013869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}